Form 4 for IGC IGC Pharma, Inc.
Accepted 2026-07-01 09:01:05 ET · period of report 2026-06-30 · accession 0001185185-26-002765 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 09:01 | 2026-06-30 | IGC | Mukunda Ram | CEO, Dir | A - Grant | $0.27 | +2.23M | 6.88M | +48% | +$601.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | A | A | 2,226,475 | $0.27 | 6,875,563 | D | — | — | (F1) Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $601,148 of outstanding indebtedness owed by the Issuer to the Reporting Person. The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3. |